Expertise in
31
conditions

Dr. Christopher J. Anker

Radiation Oncology
University Of Vermont Medical Center
111 Colchester Ave, 
Burlington, VT 
Accepting New Patients
Offers Telehealth
Expertise in
31
conditions
University Of Vermont Medical Center
111 Colchester Ave, 
Burlington, VT 

Overview

Christopher Anker is a Radiation Oncologist practicing medicine in Burlington, Vermont.

Dr. Anker is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Anal Cancer, Pleuropulmonary Blastoma, Posterior Fossa Tumor, and Liver Embolization.

He is actively involved in clinical research, co-authoring 73 peer reviewed articles and participating in 8 clinical trials. Dr. Anker is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Therapeutic Radiology in UT

Hospital Affiliations

Northwestern Medical Center Inc
Univ. Of Vermont - Fletcher Allen Health Care
Central Vermont Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

University of Vermont Medical Center
111 Colchester Ave, Burlington, VT 05401
Other Locations
Central Vermont Medical Center
130 Fisher Rd, Berlin, VT 05602

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: July 13, 2026
Intervention Type: Radiation
Study Phase: Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: January 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
View 7 Less Clinical Trials

73 Total Publications

Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Adjuvant Therapy for Resected Adenocarcinoma of the Pancreas.
Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Adjuvant Therapy for Resected Adenocarcinoma of the Pancreas.
Journal: American journal of clinical oncology
Published: August 20, 2026
Similar Doctors
Expertise in
24
conditions
Dr. Carl J. Nelson
Radiation Oncology
Expertise in
24
conditions
Dr. Carl J. Nelson
Radiation Oncology
Referral may be required

University Of Vermont Medical Center

111 Colchester Ave, 
Burlington, VT 
 (0.1 miles away)
802-847-3506
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carl Nelson is a Radiation Oncologist practicing medicine in Burlington, Vermont. He has been practicing medicine for over 18 years. Dr. Nelson is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Astrocytoma, Pleuropulmonary Blastoma, and Embryonal Tumor with Multilayered Rosettes. Dr. Nelson is currently accepting new patients.

Expertise in
10
conditions
Dr. Havaleh M. Gagne
Radiation Oncology
Expertise in
10
conditions
Dr. Havaleh M. Gagne
Radiation Oncology
Referral may be required

University Of Vermont Medical Center

111 Colchester Ave, 
Burlington, VT 
 (0.1 miles away)
802-847-3506
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Havaleh Gagne is a Radiation Oncologist practicing medicine in Burlington, Vermont. Dr. Gagne is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Laryngeal Cancer. Dr. Gagne is currently accepting new patients.

Expertise in
6
conditions
Dr. Harold J. Wallace
Radiation Oncology
Expertise in
6
conditions
Dr. Harold J. Wallace
Radiation Oncology
Referral may be required

University Of Vermont Medical Center

111 Colchester Ave, 
Burlington, VT 
 (0.1 miles away)
802-656-3506
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Harold Wallace is a Radiation Oncologist practicing medicine in Burlington, Vermont. Dr. Wallace is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Muscle Invasive Bladder Cancer. Dr. Wallace is currently accepting new patients.

Frequently Asked Questions about Dr. Christopher J. Anker

How do I make an appointment with Dr. Christopher J. Anker?

You can book an appointment with Dr. Christopher J. Anker by calling their office at 802-847-3506. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Christopher J. Anker a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Christopher J. Anker is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Christopher J. Anker specialize in?

While Dr. Christopher J. Anker is a Radiation Oncology, they have specific expertise in Lung Cancer, Anal Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Christopher J. Anker participate in research or clinical trials?

Yes. Dr. Christopher J. Anker has published 73 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Christopher J. Anker's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Christopher J. Anker accept my insurance?

Dr. Christopher J. Anker accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 802-847-3506 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Anker's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile